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THE CHOCOLATE COATED PILL
Roger H. Smith, B.Sc.
From a dissertation on the side effects of Oral Contraceptives, read before the Society on 
Friday, 2nd December, 1966
The great increase in the world birth rate 
that is presently taking place, and which 
increases the population by 165,000 people per 
day, has been estimated to double the total 
human population by the turn of the century. 
The problems set by such a rise in numbers is 
not confined to the East or to the “ under­
developed” countries of Africa, but is calcul­
ated to increase the population of Britain by 
50% in those same thirty-odd years.
Clearly, something has to be done to check 
this growth which far outstrips the foreseeable 
increase in food resources, and even more 
clearly the answer is birth control, in one way 
or another. In Britain at present the control 
is largely by two methods, the oral contra­
ceptive and the intrauterine device (IUD), so 
that in 1965 over 500,000 women in this country 
were taking one or other form of pill at some 
time, and 400,000 took pills over a 12  month 
period without a break. But at the same time, 
the Pill has come in for much adverse criticism 
for its possible or actual side effects in both 
the lay and the scientific press, and as a result, 
there has grown suspicion and fear in many 
women and not a few doctors whose job it is 
to prescribe the Pill.
THE P IL L S
In Britain the main drugs in use are com­
bined progestin/oestrogen preparations, taken 
between days five and twenty-five of the 
menstrual cycle. Nine such preparations are 
approved by the Council for the Investigation 
of Fertility Control (C IFC ), the research 
branch of the FPA. This paper will consider 
the evidence regarding the side effects of this 
type of pill alone.
Another type of Pill has recently been 
developed and marketed, known as the 
Sequential Therapy type, where pure progestin 
is given between clays 5 - 2 0  followed by five 
days of combined pills. But a certain failure 
rate does not allow as much confidence in these 
as in the combined forms, and for this reason 
only the combined form will be considered.
P O SS IBL E SIDE EF FEC T S
There are well established side effects to the 
Pill, such as initial nausea and vomiting in 
some women, but there are other effects not so 
well established, like liver damage, increased 
risk of thrombo-embolic disease, weight gain 
and other metabolic changes; this paper seeks 
to correlate the evidence available regarding 
these doubtful effects.
WEIGHT CAIN
It has been said that the weight gain during 
oral contraceptive therapy presents no problem. 
It was a man who said it, and not a woman,
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Progestin mg.
Oestrogen additive 
M estranol E thyinyl O estra- 
mg. diol mg. Trade Name
Lynestranol .......................... 5.0 0.15 — Lyndiol
M egestrol .......................... 4.0 — 0.05 Volidan
N oreth isterone ................. 2.0 0.10 — Orthonovin
N oreth isterone ac ............ 2.5 — 0.05 N orlestrin
N oreth isterone ac ............ 4.0 — 0.05 Anovlar
N orethynodrel ................. 2.5 0.10 — Conovid E
& Previson
N orethynodrel ................. 5.0 0.075 — Conovid
Ethynodiol diac ................. 1.0 0.1 — Ovulen
Fig. 1. Com bined Therapy Pills approved by C.I.F.C.
and it was in a medical rather than a philoso­
phical context that it was said. W hen we talk 
about a weight gain we must consider the age 
group and sex of the subjects involved, and here 
we are dealing with women between the ages 
of 16  and 50, the very people to whom any 
weight gain seems im portant. So that, far from 
presenting no problem, weight gain could prove 
to be a deciding factor to any woman consid­
ering whether to take the Pill for the first time, 
or whether to continue taking it having once 
started therapy. Before we pass this off as of 
m inor importance, we should at least examine 
the incidence and extent of weight gains dur­
ing therapy, and investigate the cause and 
nature of the gain.
In a recent study, the C .I .F .C . found that 
treatment with Anovlar is associated with a 
high incidence of weight gain; of 156  patients 
studied, 4 6%  put on more than 3lbs, and 22% 
gained more than 7 lbs. Liggins, using larger 
doses of Anovlar in the treatment of dysfunc­
tional uterine bleeding, found general increases 
of weight of up to g lbs., and one case of a 
gain of 20 lbs., all over similar periods of time. 
B ut W isem an has found that treatm ent with 
com pounds other than Anovlar, such as Con- 
ovid or O vulen, give equivocal results, weight 
gains over 3 lbs. being matched by a similar 
incidence of weight loss greater than 3 lbs.
W h ile  com paring their actions in a different 
context, Jackson found that Anovlar had a 
predom inately progesterone-like influence on 
the reproductive organs but Conovid gave a 
more oestrogenic picture. Thus, in those 
women on Anovlar there was a dormant, hypo­
plastic endom etrium , with thick, scanty cervical 
mucus, while women on Conovid had cornified 
vaginal epithelium  and proliferative endom e­
trium.
It is conceivable that weight gain in Anovlar 
therapy, then, is the expression of progcsterone- 
like properties of its progestin, Norethisterone, 
while the progestin of Conovid, or of Ovulen, 
having less progesterone-like activity and more 
oestrogenic properties, would not be expected 
to stim ulate a gain in weight. Such a hypothesis 
is supported by evidence which suggests that 
Progesterone itself is an anabolic agent.
Dewar has shown conclusively that the m ain­
tenance of the weight gain of pregnancy in 
mice is dependent upon circulating Progest­
erone; furthermore, Progesterone administered 
to male and non-pregnant fem ale mice pro­
duced weight gain, and this gain was 
uninfluenced by coincident oestrogen adminis­
tration. Such gains were associated with 
increased appetite, and were the “ m anifest­
ations”  of the accumulation of body fat and 
body water, regardless of diet. On unrestricted 
diets there were also increases in body protein.
During human pregnancy, the m other’s 
weight gain is associated with rising blood 
Progesterone levels; not all of this weight gain 
is due to increased body water for there is a 
considerable increase in body nitrogen. T h e 
weight gain of oral contraceptive therapy would 
likewise seem to be anabolic, at least in part, for 
the fall in weight which follows the cessation 
of therapy in such cases is slow, spread over 
several weeks or months, and its rate of fall 
is not affected to any significant degree by the 
application of diuretics.
T hese lines of evidence suggest that pro­
gesterone-like therapy, including some oral 
contraceptives, can be expected to carry with 
it the possibility of weight gain of an anabolic 
nature. But a further factor may act in addition 
to anabolic influence, per se.; that is, increased 
appetite. T h e  increased appetite m ight be
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seen as part of the anabolic effect, but it might 
be preferable to think of it rather as a m ani­
festation of the general “ new lease of life”  so 
widely reported by patients introduced to oral 
contraception. If this is so, then dieting may 
often be a necessary accom panim ent of therapy.
PROGESTIN
Fig. 2
T h e  effect on appetite would also help 
explain why other studies, such as that by 
Flowers, have found weight gains with Ovulen 
and other products other than Anovlar; indeed, 
one woman out of 200 on Ovulen gained 20 lbs. 
in three months.
T h e  conclusion, then, must be that weight 
gain can be a medical problem, and hence 
women or oral contraceptive therapy should be 
followed up; and usually the problem is a 
psychological one to the patient, which might 
call for advice. In order to give advice where 
it is needed we must be presented with more 
hard facts from large scale studies of weight 
and appetite in treated women, and, where 
gains occur, of the nature of this gain.
B L O O D  C O A G U L A B I L I T Y
M uch has been made of the assertion that 
synthetic steroids might increase blood coagul­
ability. W h ile  reporting in the medical journals 
has stimulated a proper study of the problem, 
the reaction to the advertising in the news­
papers has bred a fear of oral contraceptives 
in m any women. T w o lines of study have 
been pursued :
(1) a large scale statistical comparison of the 
incidence of thrombo-embolic disease in 
women taking oral contraceptives and 
those of the same age-group not under­
going therapy.
(2) haematological investigations in the 
treated and non-treated groups.
( 1 )  H a e m a t o l o g y
Behind the word “ coagulability”  there are
two primary processes of remarkably similar 
com plexity, coagulation and fibrinolysis. Each 
comprises of a system of precursors and activ­
ators; each depends upon successive steps of 
activation; in each there is a num ber of negative 
systems tending to antagonise the various 
activation steps and products. T h e  two pro­
cesses are currently thought to be in dynamic 
equilibrium in the circulating blood, pivoting 
round the fibrin molecule: the one process 
forms the clot, the other destroys it. Any 
change in blood coagulability is the result of 
an upset of this normal equilibrium. In assess­
ing the effect of an increased activity of any one 
part of either system, one must consider 
whether there is not also a change in the 
activity of a factor or factors in the opposing 
system. In any event, the interpretation of 
such a rise within its own system is a very 
difficult task.
T h e only factor which has consistently been 
shown to change is factor V I I  of the coagul­
ation system; its blood concentration increases. 
N o other coagulating factor has been demon­
strated to change in any reproducible manner. 
Factor V I I  also increases in pregnancy, and is 
increased in patients with recent D V T  (“ Deep 
Venous Throm bosis” ), but only in these latter 
cases has there been demonstrated a shortening 
of the heparin clotting time. I f  an increase in 
factor V I I ,  per se, is contributory to greater 
clotting tendencies, such increases as have been 
shown still cannot be said to constitute satis­
factory evidence for increased coagulability. 
There is neither any information regarding the 
state of the fibrinolytic system during therapy, 
nor of any influence that the synthetic steroids 
might have on the antithrombin and other 
systems.
Bleeding time Clotting time
Therapy No. (secs) (secs)
Control ...........  26 145 ± 8.21 278.8 ±10.7
Medication .......  39 116.8+ 6.31 261.5± 7.02
3 - 8  months Post
Medication ... 10 103.4 ±12.4 223.9 ±15.5
Fig. 3. Significant results (bold type) found with 
10 mg Conovid Dosage (after Pincus, 1956).
T h e only information that can safely be 
accepted as evidence either way is that showing 
change in clotting or bleeding times. Pincus, in 
his classical trials using Conovid, did find 
shortening of bleeding and clotting times, but 
using 10  mg doses rather than the 5 mg used
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You already know
Lyndiol 2.5 to be the ora! contraceptive 
with the lowest incidence of side-effects, 
the most reasonable price-to-patient 
and the dosage scheme most likely to 
ensure patient reliability
But did you also know 
that Lyndiol 2.5 is
MADE IN SCOTLAND!
lynestrenol 2.5 mg, mestranol 0.075 mg.
Detailed professional and patient literature gladly sent on request
Organon Laboratories Limited 
Newhouse • Motherwell • Lanarkshire
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in  more modern therapy. N o such results were 
found in the studies of Egeberg or of T h om p­
son whose work is referred to above.
(2) Statistical Surveys
Agencies of the U .S. G overnm ent have 
carried out large scale statistical surveys, and 
have concluded that “ there is no increase in 
the incidence of throm botic disease in women 
taking oral contraceptives compared with the 
incidence in non-pregnant women of the same 
age group who are not treated” .
There have been many isolated reports of 
thrombo-embolic disease in treated 'women, 
but it is im portant to consider that a certain 
incidence is in any case expected in women of 
this age group, whether or not they are taking 
the pill. It is the view of the D unlop C om ­
m ittee that the incidence in treated women is 
indeed just that expected on this basis; but the 
Com m ittee is nevertheless urging that all 
thrombo-embolic incidents in treated women 
should be reported. However, by the time 
statistical analysis is possible and is available, it 
is likely that the present form  of pill will be 
obsolete.
H E P A T O X IC IT Y
M any drugs have been shown to be toxic to 
the liver, a fact that should not be surprising, 
fo r the liver is the main site of drug detoxic­
ation and excretion, and it is the first port of 
call for oral drugs once absorbed into the blood. 
Cholestatic jaundice of a non-sensitive type has 
been shown to develop in relation to therapy 
with the general group of steroids alkylated at 
the C -17  position, to which group belong most 
of the progestins presently used in oral con­
traceptive preparations. T h e  general rule is 
that the C - 17  alkylated steroids cause liver 
damage if given often enough and in sufficient 
amounts, so that the problem here is whether
the amounts of these compounds in the various 
pills constitute a risk of hepatoxicity.
M any studies have been carried out attem pt­
ing to determine just this one sim ple fact, only 
to find that the answer is not so simple. 
There seems to be no com m on plan to the 
studies, each one having employed a different 
drug or com bination of drugs on different 
groups of women in different countries and 
using different criteria for liver damage. But, 
com plicated as this m ight seem, it is possible 
to draw certain conclusions on the subject, and 
to see certain general trends.
Scandinavian workers have been able to 
demonstrate quite widespread liver damage in 
treated women, while elsewhere the conclusion 
has been that there is no danger of associated 
hepatoxicity during normal contraceptive 
therapy. In Finland, abnormally raised serum 
transaminase levels were found by Eisalo et al 
in all of seven post-menopausal women treated, 
and by Palva and M ustala in five. Eisalo gave 
one or two tabs, per day of Lyndiol; Palva 
used Anovlar. Eisalo was later able to repro- 
duce his results in a number of cyclical women 
between the ages of 17  - 52 using Volidan as 
well as Lyndiol or Lynestranol.
O ther isolated reports have come from 
Scandinavia, so that it has been suggested that 
the apparent high incidence of liver damage 
there might be connected with the fact that 
viral hepatitis takes an unusually virulent form 
in this geographical area. However, Borglin in 
Sweden has not been able to dem onstrate hepa- 
toxicity in patients on Lyndiol.
In a British report on liver damage, by Aascher 
and Cuthbert, five post-menopausal women had 
been treated with Anovlar; their ages were 
between 62 - 80. Stoll in Australia produced
Fig. 4. Abnormal results of liver function tests 
(Eisalo et al 1965)
DRUG Total
Patients
SGOT SGPT
No. of 
Abnormals
Units
(mean)
No. of 
Abnormals
Units
(mean)
Volidan ......................................... 45 0 2 52-73
(62.5)
Lyndiol ......................................... 39 6 43-79 7 41-115
(58) (68.2)
Lynestranol ................................ 25 1 42 1 69
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liver damage in treating breast cancer with 6 
tabs per day of Lyndiol, equal to 30 m g 
lynestranol +  0.9 mg mestranol; clearly this 
represents an abnormally massive dose, but it 
docs serve to illustrate that these are potentially 
very dangerous drugs.
T hus there would seem to be two important 
factors in the aetiology of liver damage in 
treated women; one a possible post-menopausal 
predisposition to drug induced intra-hepatic 
cholestasis, and the other the possible predis­
position due to previous liver disease. A  third 
possibility has been suggested, that Scandin­
avian women, and post-menopausal women in 
general, share some common enzyme deficiency.
M ore reassuring are the results of a large 
scale study, by Tyler in Los Angeles, which 
covers eight years of observation. T yler reports 
a general incidence of abnormal liver function, 
but in each case the changes have been of the 
order expected in normal pregnancy; it seems 
fair to conclude that these changes, due to a 
variety of preparation, m ight not be patho­
logical but attributable rather to the pseudo- 
pregnant state. M ore specifically, he studied 
6,500 cycles in 435 women on Orthonovin 
over a period of 3 years, during which time he 
found no abnormality which could cause alarm, 
and certainly no indication in any patient that 
the pill should be discontinued by reason of 
liver damage. Swyer and L ittle  working in 
Britain have failed to demonstrate any liver 
m alfunction in a group of 12  women treated
for a m inim um  period of 3 years. Similarly, 
workers in other parts of the world outside 
Scandinavia have failed to find evidence of liver 
damage in normal treatment.
Thus, apart from incidences in post-meno­
pausal women, or where large doses of drugs 
have been used, the only reports of hepatic 
dysfunction have com e from Scandinavia, and 
from Finland in particular. T h e  pill would 
therefore seem to be safe as a contraceptive 
except for the one exception of women with 
a history of liver disease.
C O N C L U S I ON
Having investigated the three problems of 
weight gain, thrombo-embolic disease and liver 
damage, it is apparent that there is little in the 
way of definite scientifically based conclusion 
to be made. W h ile  the scanty evidence avail­
able at present allows of reasonable generalis­
ation, it also calls for more investigation. 
Another twenty years of study could clarify the 
im plications of therapy, but by that tim e the 
present form of the pill will have been super­
seded.
N ot every woman taking the pill is destined 
to becom e obese and yellow, with massive 
D V T ; it would be unrealistic to think so. But 
it would be equally ill-informed to ignore the 
real risks. However, the risks that seem to 
operate are greatly outweighed by the trem ­
endous social the therapeutic advantages of 
oral contraceptive therapy.
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DIAGNOSTIC PROBLEM (fro m  page 3 1 )
Diagnosis :
Adrenocortical hyperfunction. Confirm ed by 
the finding of an elevated cortisol secretion rate 
together with high levels of urinary 17-hydroxy- 
corticosteroids. In addition the diurnal varia­
tion of plasma 17-hydroxycorticosteroids was 
found to be absent although the absolute values 
were just within the upper range of normal.
T o  determine the site of the underlying 
pathological lesion, the full range of available 
tests was carried out. Space precludes their
discussion here, but in the event the most 
telling evidence was provided by a presacral 
aerogram which disclosed the presence of an 
abnorm ally enlarged right adrenal gland. R ight 
adrenalectomy was carried out with the removal 
of a 28 G . cortical adenoma. Som e difficulty 
was subsequently experienced in discontinuing 
exogenous steriod therapy, but otherwise the 
patient made an excellent recovery with resolu­
tion of all presenting complaints together with 
restoration of blood pressure to normal levels.
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